ARTICLE | Company News
Tesaro, Merck deal
June 29, 2015 7:00 AM UTC
The companies partnered to evaluate Tesaro’s niraparib ( MK-4827) in combination with Merck’s melanoma drug Keytruda pembrolizumab in a Phase I/II trial to treat triple-negative breast cancer or ovar...